A unique histone deacetylase inhibitor alters microRNA expression and signal transduction in chemoresistant ovarian cancer cells

References

• Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009; 10:32 - 42; http://dx.doi.org/10.1038/nrg2485; PMID: 19065135
   PubMed Web of Science ®Google Scholar
• Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26:5541 - 52; http://dx.doi.org/10.1038/sj.onc.1210620; PMID: 17694093
   PubMed Web of Science ®Google Scholar
• Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007; 25:84 - 90; http://dx.doi.org/10.1038/nbt1272; PMID: 17211407
   PubMed Web of Science ®Google Scholar
• Schrump DS. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin Cancer Res 2009; 15:3947 - 57; http://dx.doi.org/10.1158/1078-0432.CCR-08-2787; PMID: 19509170
   PubMed Web of Science ®Google Scholar
• Lu Q, Wang DS, Chen CS, Hu YD, Chen CS. Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem 2005; 48:5530 - 5; http://dx.doi.org/10.1021/jm0503749; PMID: 16107152
   PubMed Web of Science ®Google Scholar
• Yang YT, Balch C, Kulp SK, Mand MR, Nephew KP, Chen CS. A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer. Neoplasia 2009; 11:552 - 63, 3, 563; PMID: 19484144
   PubMed Web of Science ®Google Scholar
• Sargeant AM, Rengel RC, Kulp SK, Klein RD, Clinton SK, Wang YC, et al. OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2008; 68:3999 - 4009; http://dx.doi.org/10.1158/0008-5472.CAN-08-0203; PMID: 18483287
   PubMed Web of Science ®Google Scholar
• Lu YS, Kashida Y, Kulp SK, Wang YC, Wang D, Hung JH, et al. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology 2007; 46:1119 - 30; http://dx.doi.org/10.1002/hep.21804; PMID: 17654699
   PubMed Web of Science ®Google Scholar
• Bai LY, Omar HA, Chiu CF, Chi ZP, Hu JL, Weng JR. Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells. Cancer Chemother Pharmacol 2011; 68:489 - 96; http://dx.doi.org/10.1007/s00280-010-1501-z; PMID: 21072520
   PubMed Web of Science ®Google Scholar
• Zimmerman B, Sargeant A, Landes K, Fernandez SA, Chen CS, Lairmore MD. Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma. Leuk Res 2011; 35:1491 - 7; http://dx.doi.org/10.1016/j.leukres.2011.07.015; PMID: 21802726
   PubMed Web of Science ®Google Scholar
• Liu YL, Yang PM, Shun CT, Wu MS, Weng JR, Chen CC. Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma. Autophagy 2010; 6:1057 - 65; http://dx.doi.org/10.4161/auto.6.8.13365; PMID: 20962572
   PubMed Web of Science ®Google Scholar
• Jacob A, Oblinger J, Bush ML, Brendel V, Santarelli G, Chaudhury AR, et al. Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas. Laryngoscope 2012; 122:174 - 89; http://dx.doi.org/10.1002/lary.22392; PMID: 22109824
   PubMed Web of Science ®Google Scholar
• Takai N, Narahara H.. Histone deacetylase inhibitor therapy in epithelial ovarian cancer. J Oncol 2010; 2010:458431
   PubMedGoogle Scholar
• Balch C, Nephew KP. The role of chromatin, microRNAs, and tumor stem cells in ovarian cancer. Cancer Biomark 2010; 8:203 - 21; PMID: 22045354
   PubMed Web of Science ®Google Scholar
• Bots M, Johnstone RW. Rational combinations using HDAC inhibitors. Clin Cancer Res 2009; 15:3970 - 7; http://dx.doi.org/10.1158/1078-0432.CCR-08-2786; PMID: 19509171
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128:683 - 92; http://dx.doi.org/10.1016/j.cell.2007.01.029; PMID: 17320506
   PubMed Web of Science ®Google Scholar
• Corney DC, Hwang CI, Matoso A, Vogt M, Flesken-Nikitin A, Godwin AK, et al. Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res 2010; 16:1119 - 28; http://dx.doi.org/10.1158/1078-0432.CCR-09-2642; PMID: 20145172
   PubMed Web of Science ®Google Scholar
• Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007; 67:8699 - 707; http://dx.doi.org/10.1158/0008-5472.CAN-07-1936; PMID: 17875710
   PubMed Web of Science ®Google Scholar
• Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A 2008; 105:7004 - 9; http://dx.doi.org/10.1073/pnas.0801615105; PMID: 18458333
   PubMed Web of Science ®Google Scholar
• Cowden Dahl KD, Dahl R, Kruichak JN, Hudson LG. The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells. Neoplasia 2009; 11:1208 - 15; PMID: 19881956
   PubMed Web of Science ®Google Scholar
• Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008; 14:2690 - 5; http://dx.doi.org/10.1158/1078-0432.CCR-07-1731; PMID: 18451233
   PubMed Web of Science ®Google Scholar
• Sampath D, Liu C, Vasan K, Sulda M, Puduvalli VK, Wierda WG, et al. Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood 2012; 119:1162 - 72; http://dx.doi.org/10.1182/blood-2011-05-351510; PMID: 22096249
   PubMed Web of Science ®Google Scholar
• Rhodes LV, Nitschke AM, Segar HC, Martin EC, Driver JL, Elliott S, et al. The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells. Oncol Rep 2012; 27:10 - 6; PMID: 21971930
   PubMed Web of Science ®Google Scholar
• Shin S, Lee EM, Cha HJ, Bae S, Jung JH, Lee SM, et al. MicroRNAs that respond to histone deacetylase inhibitor SAHA and p53 in HCT116 human colon carcinoma cells. Int J Oncol 2009; 35:1343 - 52; PMID: 19885557
   PubMed Web of Science ®Google Scholar
• Lee EM, Shin S, Cha HJ, Yoon Y, Bae S, Jung JH, et al. Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells. Int J Mol Med 2009; 24:45 - 50; PMID: 19513533
   PubMed Web of Science ®Google Scholar
• Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 2006; 66:1277 - 81; http://dx.doi.org/10.1158/0008-5472.CAN-05-3632; PMID: 16452179
   PubMed Web of Science ®Google Scholar
• Diederichs S, Haber DA. Sequence variations of microRNAs in human cancer: alterations in predicted secondary structure do not affect processing. Cancer Res 2006; 66:6097 - 104; http://dx.doi.org/10.1158/0008-5472.CAN-06-0537; PMID: 16778182
   PubMed Web of Science ®Google Scholar
• Pe’er D, Hacohen N. Principles and strategies for developing network models in cancer. Cell 2011; 144:864 - 73; http://dx.doi.org/10.1016/j.cell.2011.03.001; PMID: 21414479
   PubMed Web of Science ®Google Scholar
• Ulitsky I, Maron-Katz A, Shavit S, Sagir D, Linhart C, Elkon R, et al. Expander: from expression microarrays to networks and functions. Nat Protoc 2010; 5:303 - 22; http://dx.doi.org/10.1038/nprot.2009.230; PMID: 20134430
   PubMed Web of Science ®Google Scholar
• Ovcharenko I, Nobrega MA, Loots GG, Stubbs L. ECR Browser: a tool for visualizing and accessing data from comparisons of multiple vertebrate genomes. Nucleic Acids Res 2004; 32:Web Server issue W280-6; http://dx.doi.org/10.1093/nar/gkh355; PMID: 15215395
   PubMedGoogle Scholar
• Wang X, Xuan Z, Zhao X, Li Y, Zhang MQ. High-resolution human core-promoter prediction with CoreBoost_HM. Genome Res 2009; 19:266 - 75; http://dx.doi.org/10.1101/gr.081638.108; PMID: 18997002
   PubMed Web of Science ®Google Scholar
• Maere S, Heymans K, Kuiper M. BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics 2005; 21:3448 - 9; http://dx.doi.org/10.1093/bioinformatics/bti551; PMID: 15972284
   PubMed Web of Science ®Google Scholar
• Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003; 2:151 - 63; PMID: 12589032
   PubMed Web of Science ®Google Scholar
• Choi YL, Bocanegra M, Kwon MJ, Shin YK, Nam SJ, Yang JH, et al. LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. Cancer Res 2010; 70:2296 - 306; http://dx.doi.org/10.1158/0008-5472.CAN-09-3141; PMID: 20215510
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102:15545 - 50; http://dx.doi.org/10.1073/pnas.0506580102; PMID: 16199517
   PubMed Web of Science ®Google Scholar
• Anderson K, Lawson KA, Simmons-Menchaca M, Sun L, Sanders BG, Kline K. Alpha-TEA plus cisplatin reduces human cisplatin-resistant ovarian cancer cell tumor burden and metastasis. Exp Biol Med (Maywood) 2004; 229:1169 - 76; PMID: 15564444
   PubMed Web of Science ®Google Scholar
• Arafa SA, Zhu Q, Barakat BM, Wani G, Zhao Q, El-Mahdy MA, et al. Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway. Cancer Res 2009; 69:8910 - 7; http://dx.doi.org/10.1158/0008-5472.CAN-09-1543; PMID: 19903849
   PubMed Web of Science ®Google Scholar
• Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 2004; 22:4700 - 10; http://dx.doi.org/10.1200/JCO.2004.04.070; PMID: 15505275
   PubMed Web of Science ®Google Scholar
• Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, Orlowska-Volk M, et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 2005; 24:1053 - 65; http://dx.doi.org/10.1038/sj.onc.1208298; PMID: 15558012
   PubMed Web of Science ®Google Scholar
• Warner DR, Greene RM, Pisano MM. Cross-talk between the TGFbeta and Wnt signaling pathways in murine embryonic maxillary mesenchymal cells. FEBS Lett 2005; 579:3539 - 46; http://dx.doi.org/10.1016/j.febslet.2005.05.024; PMID: 15955531
   PubMed Web of Science ®Google Scholar
• Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011; 8:97 - 106; http://dx.doi.org/10.1038/nrclinonc.2010.196; PMID: 21151206
   PubMed Web of Science ®Google Scholar
• Ying Y, Tao Q. Epigenetic disruption of the WNT/beta-catenin signaling pathway in human cancers. Epigenetics 2009; 4:307 - 12; http://dx.doi.org/10.4161/epi.4.5.9371; PMID: 19633433
   PubMed Web of Science ®Google Scholar
• Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 2010; 11:621 - 32; http://dx.doi.org/10.1038/nrm2952; PMID: 20683470
   PubMed Web of Science ®Google Scholar
• Tait SW, Green DR. Caspase-independent cell death: leaving the set without the final cut. Oncogene 2008; 27:6452 - 61; http://dx.doi.org/10.1038/onc.2008.311; PMID: 18955972
   PubMed Web of Science ®Google Scholar
• Vandenabeele P, Vanden Berghe T, Festjens N.. Caspase inhibitors promote alternative cell death pathways. Sci STKE 2006; 2006:pe44
   PubMedGoogle Scholar
• Smiley ST, Reers M, Mottola-Hartshorn C, Lin M, Chen A, Smith TW, et al. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci U S A 1991; 88:3671 - 5; http://dx.doi.org/10.1073/pnas.88.9.3671; PMID: 2023917
   PubMed Web of Science ®Google Scholar
• Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21:103 - 7; http://dx.doi.org/10.1038/5047; PMID: 9916800
   PubMed Web of Science ®Google Scholar
• Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002; 31:141 - 9; http://dx.doi.org/10.1038/ng892; PMID: 11992124
   PubMed Web of Science ®Google Scholar
• Chen MY, Liao WS, Lu Z, Bornmann WG, Hennessey V, Washington MN, et al. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer 2011; 117:4424 - 38; http://dx.doi.org/10.1002/cncr.26073; PMID: 21491416
   PubMed Web of Science ®Google Scholar
• Arzenani MK, Zade AE, Ming Y, Vijverberg SJ, Zhang Z, Khan Z, et al. Genomic DNA hypomethylation by histone deacetylase inhibition implicates DNMT1 nuclear dynamics. Mol Cell Biol 2011; 31:4119 - 28; http://dx.doi.org/10.1128/MCB.01304-10; PMID: 21791605
   PubMed Web of Science ®Google Scholar
• Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008; 27:7274 - 84; http://dx.doi.org/10.1038/onc.2008.333; PMID: 18806826
   PubMed Web of Science ®Google Scholar
• Huang PH, Chen CH, Chou CC, Sargeant AM, Kulp SK, Teng CM, et al. Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases. Mol Pharmacol 2011; 79:197 - 206; http://dx.doi.org/10.1124/mol.110.067702; PMID: 20959362
   PubMed Web of Science ®Google Scholar
• Qian X, LaRochelle WJ, Ara G, Wu F, Petersen KD, Thougaard A, et al. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther 2006; 5:2086 - 95; http://dx.doi.org/10.1158/1535-7163.MCT-06-0111; PMID: 16928830
   PubMed Web of Science ®Google Scholar
• Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010; 141:69 - 80; http://dx.doi.org/10.1016/j.cell.2010.02.027; PMID: 20371346
   PubMed Web of Science ®Google Scholar
• Cao L, Shao M, Schilder J, Guise T, Mohammad KS, Matei D. Tissue transglutaminase links TGF-β, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. [Epub ahead of print] Oncogene 2011; http://dx.doi.org/10.1038/onc.2011.429; PMID: 21963846
   PubMed Web of Science ®Google Scholar
• Stronach EA, Chen M, Maginn EN, Agarwal R, Mills GB, Wasan H, et al. DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. Neoplasia 2011; 13:1069 - 80; PMID: 22131882
   PubMed Web of Science ®Google Scholar
• Hrzenjak A, Kremser ML, Strohmeier B, Moinfar F, Zatloukal K, Denk H. SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway. J Pathol 2008; 216:495 - 504; http://dx.doi.org/10.1002/path.2434; PMID: 18850582
   PubMed Web of Science ®Google Scholar
• Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih IeM, Zhang Y, et al. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One 2008; 3:e2436; http://dx.doi.org/10.1371/journal.pone.0002436; PMID: 18560586
   PubMed Web of Science ®Google Scholar
• Galimberti S, Canestraro M, Maffei R, Marasca R, Guerrini F, Piaggi S, et al. Vorinostat interferes with Wnt and NF-kappaB pathways in the M-07e cell line. Leukemia 2009; 23:1935 - 8; http://dx.doi.org/10.1038/leu.2009.119; PMID: 19626048
   PubMed Web of Science ®Google Scholar
• Sikandar S, Dizon D, Shen X, Li Z, Besterman J, Lipkin SM. The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling. Oncotarget 2010; 1:596 - 605; PMID: 21317455
   PubMed Web of Science ®Google Scholar
• Wiltse J. Mode of action: inhibition of histone deacetylase, altering WNT-dependent gene expression, and regulation of beta-catenin--developmental effects of valproic acid. Crit Rev Toxicol 2005; 35:727 - 38; http://dx.doi.org/10.1080/10408440591007403; PMID: 16417040
   PubMed Web of Science ®Google Scholar
• Tysnes BB. Tumor-initiating and -propagating cells: cells that we would like to identify and control. Neoplasia 2010; 12:506 - 15; PMID: 20651980
   PubMed Web of Science ®Google Scholar
• Zhao Z, Zuber J, Diaz-Flores E, Lintault L, Kogan SC, Shannon K, et al. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev 2010; 24:1389 - 402; http://dx.doi.org/10.1101/gad.1940710; PMID: 20595231
   PubMed Web of Science ®Google Scholar
• Krizhanovsky V, Lowe SW. Stem cells: The promises and perils of p53. Nature 2009; 460:1085 - 6; http://dx.doi.org/10.1038/4601085a; PMID: 19713919
   PubMed Web of Science ®Google Scholar
• Condorelli F, Gnemmi I, Vallario A, Genazzani AA, Canonico PL. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br J Pharmacol 2008; 153:657 - 68; http://dx.doi.org/10.1038/sj.bjp.0707608; PMID: 18059320
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV, Trostel S, Kayastha G, Demidenko ZN, Vassilev LT, Romanova LY, et al. Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. Cancer Res 2005; 65:7386 - 92; http://dx.doi.org/10.1158/0008-5472.CAN-04-3433; PMID: 16103091
   PubMed Web of Science ®Google Scholar
• Li D, Marchenko ND, Moll UM. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ 2011; 18:1904 - 13; http://dx.doi.org/10.1038/cdd.2011.71; PMID: 21637290
   PubMed Web of Science ®Google Scholar
• Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007; 26:745 - 52; http://dx.doi.org/10.1016/j.molcel.2007.05.010; PMID: 17540599
   PubMed Web of Science ®Google Scholar
• Turley EA, Veiseh M, Radisky DC, Bissell MJ. Mechanisms of disease: epithelial-mesenchymal transition--does cellular plasticity fuel neoplastic progression?. Nat Clin Pract Oncol 2008; 5:280 - 90; http://dx.doi.org/10.1038/ncponc1089; PMID: 18349857
   PubMedGoogle Scholar
• Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 2006; 66:11954 - 66; http://dx.doi.org/10.1158/0008-5472.CAN-06-1666; PMID: 17178894
   PubMed Web of Science ®Google Scholar
• Thomson JM, Parker J, Perou CM, Hammond SM. A custom microarray platform for analysis of microRNA gene expression. Nat Methods 2004; 1:47 - 53; http://dx.doi.org/10.1038/nmeth704; PMID: 15782152
   PubMed Web of Science ®Google Scholar
• Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003; 19:185 - 93; http://dx.doi.org/10.1093/bioinformatics/19.2.185; PMID: 12538238
   PubMed Web of Science ®Google Scholar